952511-62-5

Basic information

• Product Name: 4-(2-methylpropyl)-3-(trifluoromethyl)benzoic acid
• Synonyms: 4-(2-methylpropyl)-3-(trifluoromethyl)benzoic acid
• CAS NO: 952511-62-5
• Molecular Weight: 246.229
• Mol File: 952511-62-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(2-methylpropyl)-3-(trifluoromethyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-methylpropyl)-3-(trifluoromethyl)benzoic acid(952511-62-5)
• EPA Substance Registry System: 4-(2-methylpropyl)-3-(trifluoromethyl)benzoic acid(952511-62-5)

Safety Data

• Hazardous Substances Data: 952511-62-5(Hazardous Substances Data)

Upstream product

• 126403-67-6 isobutylzinc (II) bromide 
• 1735-53-1 4-bromo-3-(trifluoromethyl)benzonitrile 
• 952511-89-6 4-(2-methylpropyl)-3-(trifluoromethyl)benzamide 
• 1034188-34-5 4-(2-methylpropyl)-3-(trifluoromethyl)benzamide 

Downstream Products

• 957206-17-6 4-isobutyl-3-trifluoromethylbenzoic acid methyl ester 
• 1307809-81-9 1-((3-(4-isobutyl-3-(trifluoromethyl)phenyl)-4,5-dihydronaphtho[1,2-c]isoxazol-7-yl)methyl)azetidine-3-carboxylic acid TFA 
• 1307812-82-3 3-(4-isobutyl-3-(trifluoromethyl)phenyl)-4,5-dihydronaphtho[1,2-c]isoxazole-7-carbaldehyde 
• 1307812-81-2 3-(4-isobutyl-3-(trifluoromethyl)phenyl)-7-vinyl-4,5-dihydronaphtho[1,2-c]isoxazole 
• 1307809-80-8 1-((3-(4-isobutyl-3-(trifluoromethyl)phenyl)-4,5-dihydronaphtho[1,2-c]isoxazol-7-yl)methyl)azetidine-3-carboxylic acid 

Relevant articles and documents

TRICYCLIC HETEROCYCLIC COMPOUNDS

Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS

The present invention relates to novel oxadiazole compounds of formula (I) having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.